Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activato…
| Métrica | BDRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -56.0% | -39.2% | -16.8% |
| ROA | -35.1% | -30.9% | -4.2% |
| Current Ratio | 2.03 | 2.73 | -0.70 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -35.1% | — |
| ✗Flujo de caja operativo positivo | −£6M | −£12M |
| ✓Rentabilidad sobre activos al alza | -35.1% | -38.8% |
| ✓Caja operativa/activos supera al ROA | -30.8% | ROA -35.1% |
| ✗Menos deuda a largo plazo | — | 0.8% |
| ✓Mejor liquidez (ratio corriente) | 2.03 | 1.75 |
| ✗Sin aumentar el nº de acciones | 54,861M | 4,953M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -71.7% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
Biodexa Pharmaceuticals Plc cotiza a 0.46 USD y tiene una capitalización bursátil de $1M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud